By: Alan Q. Thomas, MD
Narcolepsy is a chronic
neurologic disease associated with severe hypersomnolence and the brain’s
inability to regulate REM sleep-wake cycles. In humans it is caused by the loss
of cells located in the posterior hypothalamus that secrete the stimulating
neurotransmitter hypocretin. This destruction of hypocretin cells is thought to
be mediated by autoimmune attack, based on specific HLA association and T-cell
receptor polymorphisms. The disease has an incidence of 0.3-0.6 per 100,000
person-years. Onset is typically in the teens. It is an extremely debilitating
disease although pharmacologic treatments have improved.
Recent evidence suggests
that narcolepsy can be triggered by certain types of H1N1 vaccines. An
increased risk of narcolepsy has been associated with vaccination with
Pandemrix, a monovalent H1N1 influenza vaccine that was used by several
European countries in 2009. The increased risk was first described after an
outbreak of severe sudden onset narcolepsy in children that received Pandemrix
in Finland. Scientists have confirmed these findings in other European
countries including Sweden and England. All children affected in these studies
received Pandemrix.
Pandemrix is a product of
GlaxoSmithKline Europe. It was specifically engineered for the pandemic 2009
H1N1 season. It contains an oil-in-water emulsion adjuvant known as ASO3 which
enhances the immune system’s antibody production. No adjuvanted influenza
vaccines have been licensed or used in the US during the 2009 influenza
pandemic or at any other time. Pandemrix has not been used in the US and its
use was halted in Europe after 2009.
Research is ongoing to
elucidate the mechanism of how adjuvanted H1N1 vaccination can lead to
narcolepsy. Hypotheses include specific immune response to H1N1/ASO3 leading to
autoimmune attack of hypocretin cells in the brain. This would suggest possible
shared epitopes or molecular mimicry between the vaccine and the posterior
hypothalamic hypcretin producing cells. Alternatively, ASO3 may lead to a
generalized stimulation of the immune system. Intersetingly, an association
between streptococcal infection and recent-onset narcolepsy has been described,
in the absence of H1N1 vaccination or infection. Elevated ASO titers have been
reported in European children with post-Pandemrix vaccination narcolepsy.
In response to the events
in Europe, the CDC reviewed data from the US Vaccine Adverse Event Reporting
System (VAERS) and the Vaccine Safety Datalink (VSD). No association between
US-licensed H1N1 or seasonal influenza vaccination and narcolepsy was found.
The CDC is currently
sponsoring an international study on the associations between adjuvanted H1N1
vaccines and narcolepsy. It is expected to be complete in 2014.
The CDC continues to
recommend influenza vaccination, including H1N1, to protect from influenza
illness and severity.
·
Miller et al. Risk of
narcolepsy in children receiving an AS03 adjuvanted AH1N1 (2009) influenza
vaccine in England. (2013). British Medical Journal. http://www.bmj.com/cgi/doi/10.1136/bmj.f794
·
Partinen et al. Increased
incidence and clinical picture of childhood narcolepsy following the 2009 H1N1
pandemic vaccination campaign in Finland. PLoS One. 2012;7(3):e33723. Available
online http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0033723
·
Nohynek et al. AS03
adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of
childhood narcolepsy in Finland. PLoS One. 2012;7(3):e33536. Available online: http://www.plosone.org/article/info:doi/10.1371/ journal.pone.0033536
·
Eurosurveillance editorial
team. Swedish Medical Products Agency publishes report from a case inventory
study on Pandemrix vaccination and development of narcolepsy with cataplexy.
Euro Surveill. 2011;16(26):pii=19904. Available online: http://www.eurosurveillance.org/ViewArticle.aspx? Article Id=19904
·
ECDC Technical Report: Narcolepsy in association with pandemic influenza
vaccination, a multi-country European epidemiological investigation [PDF - 8
MB]
Dr. Alan Thomas is in
practice with Pulmonary Associates of the Southeast, PC, and is a member of the
medical staff at Trinity Medical Center.
Dr. Thomas specializes in Pulmonary Disease, Critical Care Medicine and
Sleep Medicine. He is the medical
director of the Trinity Sleep Disorders Center.
No comments:
Post a Comment